Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Naveris, Inc.

Naveris Announces Expanded Commercial Payor Coverage for NavDx® Test from Blue Shield of California
From Naveris, Inc.
Via Business Wire
Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting
From Naveris, Inc.
Via Business Wire
Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting
From Naveris, Inc.
Via Business Wire
New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings
From Naveris, Inc.
Via Business Wire
Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting
From Naveris, Inc.
Via Business Wire
CMS Designates the NavDx® Test as an Advanced Diagnostic Laboratory Test (ADLT)
From Naveris, Inc.
Via Business Wire
Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024
From Naveris, Inc.
Via Business Wire
Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024
From Naveris, Inc.
Via Business Wire
Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.
From Naveris, Inc.
Via Business Wire
Naveris Receives Medicare Coverage for NavDx® Test
From Naveris, Inc.
Via Business Wire
Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice
From Naveris, Inc.
Via Business Wire
Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings
From Naveris, Inc.
Via Business Wire
Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial
From Naveris, Inc.
Via Business Wire
Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers
From Naveris, Inc.
Via Business Wire
Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx
From Naveris, Inc.
Via Business Wire
Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting
From Naveris, Inc.
Via Business Wire
Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session
From Naveris, Inc.
Via Business Wire
Naveris' New Saliva Test Detects Head and Neck Cancer
From Naveris, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.